Evaluación del valor diagnóstico de la calprotectina fecal en pacientes con dispepsia

  1. González, Camila
  2. Vásquez, Ana 1
  3. Córdova, Diego 1
  4. Abad, Paula
  5. González, Juan 2
  6. López, Guillermo 1
  7. Cordero, Juan 1
  8. González, Esteban 1
  1. 1 Facultad de Ciencias Médicas, Universidad de Cuenca. Cuenca, Ecuador.
  2. 2 Departamento de Cirugía General, Hospital São Francisco de Assis, Belo Horizonte, Brasil.
Revista:
Maskana

ISSN: 1390-6143,  2477-8893

Ano de publicación: 2022

Volume: 13

Número: 2

Páxinas: 56-61

Tipo: Artigo

DOI: 10.18537/MSKN.13.02.06 DIALNET GOOGLE SCHOLAR lock_openDialnet editor

Outras publicacións en: Maskana

Resumo

The diagnosis of patients with dyspepsia represents a challenge since in most cases complex and costly endoscopic observations are required. In this study, we evaluated the diagnostic role of fecal calprotectin in patients with dyspepsia. To this end, an observational study was performed in 2019 on 149 patients with dyspepsia registered in the private Gastroenterology Specialists Center in Cuenca, Ecuador. The available data encompassed age, sex, alarm signs, fecal calprotectin (FC) values, and endoscopic findings. Patients in the age group >65 years were most represented, 56.4% of the population were female, 48.57% were FC positive of whom 86.8% possessed significant values of FC. FC+ was significantly associated with findings by EDA/colonoscopy (p<0.001). The most diagnostic pathologies in patients with FC+ were congestive gastropathy, intestinal metaplasia, giardiasis, and polyposis. FC correlated positively with the presence of pathological findings in the invasive diagnostic tests (r=0.298) and is a useful, noninvasive biomarker correlating positively with endoscopic findings in the gastrointestinal tract of dyspepsia patients.

Referencias bibliográficas

  • Aksoy, Ö. Y., Canan, O., Hoşnut, F. Ö., Akçay, E., & Özçay, F. (2020). Fecal calprotectin levels in Helicobacter pylori gastritis in children. The Turkish Journal of Pediatrics, 62(6), 986-993. https://doi.org/10.24953/turkjped.2020.06.010
  • Alibrahim, B., Aljasser, M. I., & Salh, B. (2015). Fecal calprotectin use in inflammatory bowel disease and beyond: A mini-review. Canadian Journal of Gastroenterology & Hepatology, 29(3), 157-163. https://doi.org/10.1155/2015/950286
  • Andréasson, K., Ohlsson, B., & Mandl, T. (2016). Elevated levels of faecal calprotectin in primary Sjögren’s syndrome is common and associated with concomitant organic gastrointestinal disease. Arthritis Research & Therapy, 18(9), págs. 6. https://doi.org/10.1186/s13075-015-0907-8
  • Ayling, R. M., & Kok, K. (2018). Fecal Calprotectin. Advances in Clinical Chemistry, 87, 161-190. https://doi.org/10.1016/bs.acc.2018.07.005
  • Caviglia, G. P., Pantaleoni, S., Touscoz, G. A., Adriani, A., Rosso, C., Smedile, A., Pellicano, R., Astegiano, M., & Bresso, F. (2014). Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders. Scandinavian Journal of Gastroenterology, 49(12), 1419-1424. https://doi.org/10.3109/00365521.2014.934913
  • Conroy, S., Hale, M. F., Cross, S. S., Swallow, K., Sidhu, R. H., Sargur, R., & Lobo, A. J. (2018). Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care. Journal of Clinical Pathology, 71(4), 316-322. https://doi.org/10.1136/jclinpath-2017-204506
  • Däbritz, J., Musci, J., & Foell, D. (2014). Diagnostic utility of faecal biomarkers in patients with irritable bowel syndrome. World Journal of Gastroenterology, 20(2), 363-375. https://doi.org/10.3748/wjg.v20.i2.363
  • Iliás, Á., Rózsa, F. P., Gönczi, L., Lovász, B. D., Kürti, Z., & Lakatos, P. L. (2019). The role of fecal calprotectin in the diagnosis and treatment of gastrointestinal diseases. Orvosi Hetilap, 160(9), 322-328. https://doi.org/10.1556/650.2019.31289
  • Jafri, L., Siddiqui, A., Sidddique, S., Parkash, O., Kausar, R., & Majid, H. (2020). Clinical spectrum in a cohort of patients with high fecal calprotectin Levels. Cureus, 12(11), e11314. https://doi.org/10.7759/cureus.11314
  • Jusué, V., Chaparro, M., & Gisbert, J. P. (2018). Accuracy of fecal calprotectin for the prediction of endoscopic activity in patients with inflammatory bowel disease. Digestive and Liver Disease: Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 50(4), 353-359. https://doi.org/10.1016/j.dld.2017.12.022
  • Kan, Y. M., Chu, S. Y., & Loo, C. K. (2021). Diagnostic accuracy of fecal calprotectin in predicting significant gastrointestinal diseases. JGH Open: An Open Access Journal of Gastroenterology and Hepatology, 5(6), 647-652. https://doi.org/10.1002/jgh3.12548
  • Larsson, G., Shenoy, K. T., Ramasubramanian, R., Thayumanavan, L., Balakumaran, L. K., Bjune, G. A., & Moum, B. A. (2014). Los niveles de calprotectina fecal diferencian la tuberculosis intestinal de la pulmonar: Un estudio observacional del sur de la India. United European Gastroenterology Journal, 2(5), 397-405. https://doi.org/10.1177/2050640614546947
  • Lundberg, J. O., Hellström, P. M., Fagerhol, M. K., Weitzberg, E., & Roseth, A. G. (2005). Technology insight: Calprotectin, lactoferrin and nitric oxide as novel markers of inflammatory bowel disease. Nature Clinical Practice. Gastroenterology & Hepatology, 2(2), 96-102. https://doi.org/10.1038/ncpgasthep0094
  • Manz, M., Burri, E., Rothen, C., Tchanguizi, N., Niederberger, C., Rossi, L., Beglinger, C., & Lehmann, F. S. (2012). Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: An observational study. BMC Gastroenterology, 12(5), 9 págs. https://doi.org/10.1186/1471-230X-12-5
  • Pavlidis, P., Chedgy, F. J., & Tibble, J. A. (2013). Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary care. Scandinavian Journal of Gastroenterology, 48(9), 1048-1054. https://doi.org/10.3109/00365521.2013.816771
  • Pereira, R., & Sevá-Pereira, T. (2016). Dor abdominal. En Tratado de Gastroenterologia (2.a ed., Vol. 1, pp. 251-263). Atheneu.
  • Pieczarkowski, S., Kowalska-Duplaga, K., Kwinta, P., Tomasik, P., Wędrychowicz, A., & Fyderek, K. (2016). Diagnostic value of fecal calprotectin (S100 A8/A9) test in children with chronic abdominal pain. Gastroenterology Research and Practice, 2016, article 8089217, 7 págs. https://doi.org/10.1155/2016/8089217
  • Prell, C., Nagel, D., Freudenberg, F., Schwarzer, A., & Koletzko, S. (2014). Comparison of three tests for faecal calprotectin in children and young adults: A retrospective monocentric study. BMJ Open, 4(5), e004558. https://doi.org/10.1136/bmjopen-2013-004558
  • Rodrigo, L. (2007). Calprotectina fecal. Revista Española de Enfermedades Digestivas, 99(12), 683-688.
  • van Rheenen, P. F., Van de Vijver, E., & Fidler, V. (2010). Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: Diagnostic meta-analysis. BMJ (Clinical Research Ed.), 341, c3369. https://doi.org/10.1136/bmj.c3369
  • Waugh, N., Cummins, E., Royle, P., Kandala, N.-B., Shyangdan, D., Arasaradnam, R., Clar, C., & Johnston, R. (2013). Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: Systematic review and economic evaluation. Health Technology Assessment (Winchester, England), 17(55), xv-xix, 1-211. https://doi.org/10.3310/hta17550
Fonte de datos: Dialnet